ストックスクリーナーアプリを入手
75.80
1.33%
-1.02
アフターアワーズ：
75.80
前日終値:
$76.82
開ける：
$77.62
24時間の取引高:
1.85M
Relative Volume:
1.04
時価総額：
$6.29B
収益：
$1.73B
当期純損益:
$682.64M
株価収益率:
9.7978
EPS:
7.7364
ネットキャッシュフロー:
$411.18M
1週間 パフォーマンス:
-2.83%
1か月 パフォーマンス:
-10.22%
6か月 パフォーマンス:
+0.41%
1年 パフォーマンス:
+69.42%
1日の値動き範囲:
$75.72
$79.33
1週間の範囲:
$75.72
$80.56
52週間の値動き範囲:
$43.17
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
75.80 | 6.37B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-17 | 開始されました | Truist | Buy |
| 2025-05-09 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-07 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
PTC Therapeutics Inc (PTCT) Balance Sheet - TradingKey
PTC Therapeutics Inc (PTCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PTC Therapeutics Inc (PTCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PTC Therapeutics Inc (PTCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PTC Therapeutics, Inc. Revenue Breakdown – BOATS:PTCT - TradingView
PTC Therapeutics Inc (PTCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PTCT|PTC Therapeutics Inc|Price:76.820|Chg%:-1.630 - TradingKey
PTC Therapeutics Inc (PTCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PTCT5396017 Bond Profile — Key Metrics - TradingView
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Barclays Remains a Buy on PTC Therapeutics (PTCT) - The Globe and Mail
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00 - GuruFocus
Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
Reasons why investors should consider betting on PTC stock now - MSN
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - Sahm
Form 4 PTC Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares By Investing.com - Investing.com South Africa
PTC Therapeutics schedules second-quarter 2026 results webcast conference call - Bitget
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares - Investing.com
PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes - Stock Titan
PTCT Maintained by Cantor FitzgeraldPrice Target Raised to $1 - GuruFocus
Cantor Fitzgerald raises PTC Therapeutics stock price target on Sephience outlook - Investing.com Canada
PTC Therapeutics Sets July 30 Webcast for Business Update - Stock Titan
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130 - Moomoo
PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders - Sahm
Form 144 PTC THERAPEUTICS For: 14 July By Investing.com - Investing.com Nigeria
PTC THERAPEUTICS, INC. SEC Filing (Jul 14, 2026) - Stock Titan
PTC Therapeutics (PTCT) Q1 2025 earnings summary - Quartr
PTC Therapeutics (PTCT) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Form 4 PTC Therapeutics Inc For: 13 July By Investing.com - Investing.com South Africa
PTC Therapeutics chief technical ops officer sells $222,376 in shares - Investing.com UK
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock - Investing.com UK
PTC Therapeutics chief technical ops officer sells $222,376 in shares By Investing.com - Investing.com Nigeria
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million - The Motley Fool
Mary L. Smith, director at PTC Therapeutics, sells $1.43m in stock By Investing.com - Investing.com South Africa
PTC Therapeutics (PTCT) director trades 15,834 shares via option exercise and sale - Stock Titan
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $91 - Moomoo
PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus - simplywall.st
PTC Therapeutics Inc (PTCT) - MSN
PTC Therapeutics (PTCT) Q3 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
PTC Therapeutics (PTCT) Q2 2024 earnings summary - Quartr
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):